2022
DOI: 10.1016/j.oraloncology.2022.106054
|View full text |Cite
|
Sign up to set email alerts
|

Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 41 publications
0
2
0
Order By: Relevance
“…A meta-analysis of 5782 patients with metastatic hormone-sensitive prostate cancer cancers showed that low Hb levels were associated with an increased risk of cancer-specific mortality, biochemical recurrence, and disease progression 28 . In patients with head and neck cancers treated with chemoradiation, pretreatment Hb below 114 g/l was identified as an independent poor prognostic factor and considered as a biomarker to predict survival outcomes 29 . Similar results were observed in our study.…”
Section: Discussionmentioning
confidence: 99%
“…A meta-analysis of 5782 patients with metastatic hormone-sensitive prostate cancer cancers showed that low Hb levels were associated with an increased risk of cancer-specific mortality, biochemical recurrence, and disease progression 28 . In patients with head and neck cancers treated with chemoradiation, pretreatment Hb below 114 g/l was identified as an independent poor prognostic factor and considered as a biomarker to predict survival outcomes 29 . Similar results were observed in our study.…”
Section: Discussionmentioning
confidence: 99%
“…Multiple authors have shown how patient variables such as age and comorbidities can influence outcomes [1,2]. But interestingly, there has been an increasing interest in using peripheral blood factors such as leukocytes, albumin or hemoglobin as surrogates of the host status in head and neck cancer patients [3–9,10 ▪▪ ,11 ▪▪ ,12,13 ▪▪ ,14–22]. Generally, these variables are gathered prior to treatment initiation.…”
Section: Introductionmentioning
confidence: 99%